BioSpace News Archive

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in the company’s Phase 1 trial of XMT-1660, the company’s Dolasynthen ADC targeting B7-H4.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced $40 million in Series C equity and debt financing.

Intellipharmaceutics International Inc announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc., by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory of Health Canada.

Aytu BioPharma, Inc. today announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,273,148 (the “‘148 patent”), for AR101/Enzastaurin.

enVVeno Medical Corporation today announced the appointment of Kevin Belteau as Vice President of Clinical Operations.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founder and former chairman and CEO of Integra LifeSciences passed away over the past weekend.

Artelo Biosciences, Inc. (Nasdaq: ARTL), today announced publication of pre-clinical results indicating a novel fatty acid binding protein 5 (FABP5) inhibitor from the Company’s FABP inhibitor platform reduces anxiety behaviors in an area of the brain known to be important in anxiety and that modulation of the FABP5 system may serve as a promising target for the development of novel anxiolytics.

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg (Cetrorelix).

Rockley Photonics Holdings Limited today announced that it will participate in the following investor conference.

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH™) trial.